Novabay Pharmaceuticals Inc ROCE
¿Qué es el ROCE de Novabay Pharmaceuticals Inc?
El ROCE de Novabay Pharmaceuticals Inc es -3,385.40%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en NYSEMKT en comparadas con Novabay Pharmaceuticals Inc
¿Qué hace Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Empresas con roce similar a Novabay Pharmaceuticals Inc
- Forum Merger III tiene ROCE de -4,294.27%
- On Track Innovations tiene ROCE de -3,978.00%
- On Track Innovations tiene ROCE de -3,978.00%
- Alpha MOS SA tiene ROCE de -3,650.00%
- Therapix Biosciences tiene ROCE de -3,621.30%
- Nymox Pharmaceutical Corp tiene ROCE de -3,533.74%
- Novabay Pharmaceuticals Inc tiene ROCE de -3,385.40%
- Akorn tiene ROCE de -3,206.05%
- Class 1 Nickel and Technologies tiene ROCE de -3,055.32%
- Major Precious Metals tiene ROCE de -3,049.61%
- Goldhills tiene ROCE de -2,716.05%
- Datasea tiene ROCE de -2,450.25%
- Datasea tiene ROCE de -2,450.25%